ASCO 2019 | Evolving paradigms in untreated multiple myeloma

During ASCO 2019, Chicago, US, the MM Hub spoke to Philip L. McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US, about the evolving treatment paradigms in newly diagnosed multiple myeloma (NDMM). He spoke firstly about the exciting news from the International Myeloma Working Group (IMWG) of a new risk stratification system for smoldering myeloma (SMM) as a way of recognizing high-risk patients. He noted this was significant as the field is evolving and we are continuously searching for factors to indicate whether patients should be treated early, or observed.

Secondly, he stated that the new data presented at ASCO by Sagar Lonial, showed lenalidomide was superior to observation alone in high-risk SMM. Lastly, Philip McCarthy discussed the risk analysis from the FORTE trial (carfilzomib + lenalidomide + dexamethasone [KRd] with or without transplant).